Coverage appeal AI
Claimable
Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.
Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.
Summary judgment · 72 out of 100 toward patient-directed
Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.
Potentially agency-expanding, with sponsorship-alignment caveat
Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.
Patient agency
How this tool changes agency
drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.
Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows.
Patient agency assessment
Who sets and changes the goal?
the documented approval gate supports patient direction within the appeal task. Provider referral and sponsorship do not erase that gate. Authority over a different treatment goal or enterprise strategy is not established.
What can the patient understand, question, or do?
drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.
Can the patient evaluate the conditions of use?
the public controls are meaningful, but contradictory sharing language and unobserved consent limit confidence in how patients evaluate the service's conditions. Commercial interests may coincide with a chosen appeal without encompassing all patient interests.
Text findings
Conditions of use
Published controls and their limits
the public controls are meaningful, but contradictory sharing language and unobserved consent limit confidence in how patients evaluate the service's conditions. Commercial interests may coincide with a chosen appeal without encompassing all patient interests.
What remains unknown?
Not tested or not established
Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows.
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://www.getclaimable.com/for-providers
- https://www.getclaimable.com/for-pharma
- https://www.getclaimable.com/provider-service-agreement
- https://www.getclaimable.com/privacy-policy
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
AI-assisted draft · Medium for published documentation, low for implementation (AI-assisted draft)